DVx Inc. (TSE:3079) has revised its earnings forecast for the full fiscal year ending March 2026, projecting higher revenue alongside lower profitability.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 52.0bn | JPY 56.0bn | +7.8% |
| Operating Profit | JPY 581M | JPY 279M | -52.0% |
| Ordinary Income | JPY 581M | JPY 299M | -48.5% |
| Net Profit | JPY 395M | JPY 189M | -52.2% |
| EPS | JPY 37.66/share | JPY 18.10/share | JPY -19.56/share |
The company attributed the revision to stronger-than-expected adoption of its pulse field ablation (PFA) technology for atrial fibrillation treatment, which altered the product mix and increased selling, general, and administrative expenses. Furthermore, rising costs due to inflation, including higher labor and outsourcing expenses, pressured margins.
The revised forecast indicates a shift in revenue composition and rising operational costs, leading to a significant decline in profitability. Management emphasized the need to enhance self-developed product offerings and improve operational efficiency to restore profitability.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.